Wyss startup Prapela is leveraging stochastic resonance technology developed at the Institute to produce an inexpensive mattress pad that delivers barely-detectable random vibrations to help soothe infants and normalize their breathing to address neonatal opioid withdrawal syndrome and infant apnea.

Little vibrations. Big impact.

Wyss startup Prapela is leveraging our stochastic resonance technology to develop an inexpensive mattress pad that delivers barely-detectable random vibrations to help soothe infants and normalize their breathing to address a variety of health conditions.

UMO, UNE, USM, Colby, Bates, and Bowdoin colleges have all used NIH funding. Also Wabanaki health&wellness, continueyou, Maine Health, MDI Bio lab, prapela, unar labs, revida therapeutics and more.

Wyss startup Prapela is leveraging stochastic resonance technology to develop a mattress pad that delivers barely-detectable random vibrations to help soothe infants and normalize their breathing to address problems such as apnea of prematurity and neonatal opioid withdrawal syndrome.

Wyss startup Prapela's vibrating mattress pad uses stochastic resonance to deliver barely detectable vibrations to infants that help to stabilize their breathing and soothe them, reducing the risk of life-threatening apnea and reducing the symptoms of neonatal opioid withdrawal syndrome.

Wyss pediatric biotech startup Prapela is leveraging stochastic resonance technology developed at the Institute to create an inexpensive mattress pad that delivers barely-detectable random vibrations to help soothe infants and normalize their breathing.

Learn about the origins of Wyss startup Prapela's vibrating mattress pad that stabilizes cardiorespiratory function more effectively and improves neonatal health in cases of apnea of prematurity and NOWS.

200K+ infants face prenatal opioid exposure yearly. Prapela’s FDA-authorized bassinet pad treats NOWS without meds using gentle vibrations to stabilize newborns’ breathing & heart rate. A #MassChallenge alum with $8M+ in support.

🎥 youtu.be/y01nAXBnrEk

🔗 masschallenge.org/articles/pra...

Proud to share an important milestone in treating opioid-exposed newborns! #Prapela #neonatalcare #medtech

Excited to share that John Konsin, CEO & Co-Founder, will be interviewed by John Parker, VP, Board of Trustees of the Charles H. Hood Foundation, to share the Prapela Story at MIT-Hood Pediatric Innovation 2025 on October 23rd!

#PediatricInnovation #Prapela #MIT #HealthTech #HoodFoundation

Neonatal Abstinence Syndrome (NAS) continues to increase in some areas, declining in others. To solve a problem, you must first measure. As the only FDA-authorized treatment to help these newborns, Prapela acknowledges California's ongoing monitoring efforts.
www.cdph.ca.gov/Programs/CFH...

This Wednesday, Prapela will be part of the Midwest Pediatric Device Consortium Showcase Event.

We owe a great deal to Ohio's pediatric community, as well as the State of Ohio. On August 27, 2019, the $1M award we received from the Ohio Opioid Technology Challenge.

We're on Capitol Hill today. Sharing our first and only FDA-authorized treatment for opioid-exposed newborns with Congress. NIH funding helped make our breakthrough a reality. www.einpresswire.com/article/8205...

Since 1973, swinging beds, bouncing chairs, and swaying cribs have failed to gain FDA clearance to treat newborns. These products are not supported by rigorous clinical evidence, can't be disinfected, and use habit-forming motions. Prapela is proud to be the first FDA-authorized device for babies.

www.einpresswire.com/article/8035...

On this World Prematurity Day, Prapela thanks the US National Institutes of Health, especially
The National Institute on Drug Abuse (NIDA), Leonardo M. Angelone and Stacie Gutowski, Ph.D. for supporting our initiative to improve the treatment of apnea of prematurity (AOP).

Keep the breakthroughs coming. Help us fund the people engineering solutions for the world’s biggest problems.

Find out how you can support our mission: bit.ly/Wyss-Giving